canSAR

Cancer translational knowledge base integrating pharmacology, bioactivity, structure, druggability.

Composite score: 89.4

Rubric (1–5 per criterion)

rigor

5/5

coverage

5/5

maintenance

4/5

adoption

4/5

quality

5/5

accessibility

3/5

industry_relevance

5/5

Metadata

Stages

Target IDHit ID

Modalities

small-moleculeprotein-general

Task types

druggabilitytarget-annotation

License

Academic free / commercial tier

First release

2011

Last updated

2024-09

Flags

none

Size & scope

proteins: 25000
compounds: 11000000
bioactivity_datapoints: 106000000

Primary paper

Title

canSAR: update to the cancer translational research and drug discovery knowledgebase

Authors

Mitsopoulos C, Di Micco P, et al.

Year

2021

DOI / arXiv

10.1093/nar/gkaa1059

Citations

210

Hosted by (initiatives)

not hosted by any tracked initiative

Experts (primary authors / maintainers)

Bissan Al-Lazikani

Groups (host labs / companies / consortia)

The Institute of Cancer Research

Related benchmarks

Notes (honest caveats)

Deep oncology focus; widely-used druggability predictor.